Most women spend four to ten years in perimenopause, and most of that time is spent without a name for what is happening. Cycles shorten. Sleep breaks apart at 3am. Anxiety appears in someone who has never been anxious. Weight settles around the middle while nothing about diet or training has changed. Hot flashes, the one symptom everyone recognizes, often arrive late — sometimes years after the transition began.
The clinical response is frequently a single hormone draw that comes back "normal," and a conclusion that nothing is wrong. That draw was close to meaningless, for a reason worth understanding. This hub covers the three stages and what actually happens in each, the panel worth running, the treatment window that changes the risk calculus, and the tests standard care skips at exactly the age they start to matter most.
The Verdict
The three stages, with real timelines
The three stages describe different physiology, not just different ages. Perimenopause is a period of hormonal instability. Postmenopause is a period of hormonal stability at a low level. Those two states produce different symptoms and call for different responses, which is why collapsing them into "menopause" causes so much confusion.
| Stage | Typical age | Duration | What is happening |
|---|---|---|---|
| Perimenopause | Typically 40–51; can start in the mid-30s | 4–10 years | Cycles shorten, then become irregular. Estradiol swings high and low rather than falling steadily. Sleep disruption, mood change and heavier or unpredictable bleeding usually arrive before hot flashes. |
| Menopause | US median age 51 (range roughly 45–55) | A single point in time | Defined retrospectively as 12 consecutive months without a period. Diagnosed by the calendar, not by a lab value. |
| Postmenopause | From 12 months after the final period onward | The rest of life | Estradiol settles low and stable. Bone loss runs fastest in the first 5 years, and cardiovascular risk begins climbing toward male-equivalent levels. |
The most commonly misunderstood point: estradiol does not decline smoothly through perimenopause. It becomes erratic. As the ovaries respond less predictably to FSH, some cycles produce estradiol levels above anything seen in a woman's 20s, and other cycles produce very little. That volatility — not deficiency — drives the heavy bleeding, breast tenderness, migraines and mood swings of early perimenopause. Deficiency symptoms such as vaginal dryness and joint pain tend to arrive later.
The full panel worth running
A useful panel at this stage is mostly not hormones. The hormone values establish context; the thyroid, iron, metabolic and cardiovascular results are the ones that most often produce a change in treatment. Ranges below are common adult reference values, with the tighter optimal targets noted where they differ.
| Marker | Range | Why it belongs on the panel |
|---|---|---|
| FSH | Rises above 25–30 IU/L as ovarian reserve falls | Useful in postmenopause. In perimenopause it can read 40 one month and 12 the next, so a single value cannot confirm or exclude the transition. |
| Estradiol | Roughly 30–400 pg/mL cycling; under 30 postmenopause | The symptom driver. During perimenopause it swings above premenopausal peaks as often as it drops, which is why symptoms can be erratic rather than progressive. |
| Progesterone | Above 3 ng/mL confirms ovulation; drawn day 19–21 | Falls earlier than estradiol. Low progesterone against fluctuating estradiol explains much of the sleep disruption, anxiety and heavy bleeding of early perimenopause. |
| Total and free testosterone | Total roughly 15–70 ng/dL | Declines gradually from the 20s, not sharply at menopause. Relevant to libido, energy and lean mass; often not measured at all in women. |
| DHEA-S | Roughly 35–430 mcg/dL, falling steadily with age | The adrenal precursor pool. Low values sit behind some low-testosterone pictures. |
| TSH, free T4, free T3, TPO antibodies | TSH roughly 0.4–4.0 mIU/L; tighter optimal band | Thyroid disease is 5–8 times more common in women and peaks at the same age as perimenopause. The symptom overlap is nearly complete. |
| Ferritin and CBC | Ferritin above 30 ng/mL minimum; 50–100 preferred | Heavy perimenopausal bleeding is a common and frequently missed cause of iron deficiency, which itself causes fatigue and brain fog. |
| Fasting insulin, HbA1c, HOMA-IR | Fasting insulin under 8 uIU/mL; HbA1c under 5.4% | Insulin sensitivity falls across the transition even when weight is stable. This shift usually precedes any change on the scale. |
| ApoB, Lp(a), lipid panel | ApoB under 80 mg/dL for average risk | LDL and ApoB rise sharply in the year around the final period. Lp(a) is measured once in a lifetime and is genetically set. |
| Vitamin D, B12, magnesium | Vitamin D 40–60 ng/mL | Correctable deficiencies that mimic or amplify transition symptoms. |
The HRT timing hypothesis
The timing hypothesis is the most decision-relevant idea in this entire subject, and it rarely comes up in a standard appointment. The proposal is that estrogen's effect on blood vessels depends on the condition of those vessels when therapy begins. In relatively healthy arteries, estrogen appears to support endothelial function. In arteries already carrying established atherosclerotic plaque, the same exposure appears less favorable.
The practical translation: therapy started within roughly 10 years of the final period, or before age 60, sits in a different risk-benefit position than therapy started 15 or 20 years out. Age-stratified re-analysis of the Women's Health Initiative found meaningfully different outcomes for women who began in their 50s compared with the trial's older average participant, who was 63 at enrollment.
This is why "wait and see if it gets bad enough" is a costly default. The decision has an expiry. A woman at 52 with disruptive symptoms is deciding inside the window. The same woman at 66 is deciding under a different set of tradeoffs, whether or not she ever chose to wait.
Two more points that follow from the same evidence. Delivery route matters: transdermal estradiol bypasses first-pass liver metabolism and has not shown the venous clotting signal associated with oral estrogen. And the progestogen matters if you have a uterus: micronized progesterone and synthetic progestins are not interchangeable in the breast-risk data.
What standard care systematically misses
These are not obscure tests. They are ordinary, inexpensive, widely available, and left off the standard panel at the exact age they become informative.
| What gets missed | What usually happens instead | Why it matters |
|---|---|---|
| Thyroid antibodies | TSH alone is ordered; TPO and thyroglobulin antibodies are not | Autoimmune thyroid disease can be present for years with a normal TSH |
| Progesterone timing | Drawn on whatever day the appointment fell | A day-5 progesterone is uninformative; day 19–21 is the window that means something |
| Testosterone and DHEA-S | Rarely ordered for women at all | Libido, energy and lean-mass complaints get attributed to age with no measurement |
| ApoB and Lp(a) | Standard lipid panel only | Cardiovascular risk changes fastest at exactly this life stage, and a standard panel can look reassuring while ApoB is high |
| Fasting insulin | Fasting glucose and HbA1c only | Insulin resistance is detectable years before glucose moves |
| Ferritin | Hemoglobin only | Iron stores can be depleted long before anemia appears on a CBC |
The cardiovascular items deserve emphasis. Women's LDL cholesterol and ApoB rise sharply in the year surrounding the final menstrual period, independent of diet or weight change. Cardiovascular disease is the leading cause of death in women, and the risk trajectory bends upward at precisely this stage. A one-time Lp(a) measurement — genetically determined, never needing a repeat — identifies the roughly one in five people carrying an elevated inherited risk that no lifestyle change will move.
Guides in this section
- The 3 stages of menopause — perimenopause, menopause, postmenopause in detail
- Perimenopause symptoms — the full list across nine body systems, including the under-recognised ones
- Perimenopause biomarker panel — what to test and when to draw it
- HRT side effects and risks — the absolute numbers behind the headlines
- When to start and stop hormone therapy: the timing window and what happens past it
- HRT cost: what each access route charges across a year
- HRT and weight gain: what the placebo-controlled trials found
- Hormonal hair loss in women — why most women who have it show a normal testosterone result
- PCOS and insulin resistance: the loop between insulin and androgens, and which markers to run
- HRT vs BHRT — what the difference actually is
- Hormone therapy platforms compared (2026) — one rubric applied to each
- Testosterone therapy for women — the one indication with society backing, and the dose-dependent side effects
- PFAS and early menopause — what the cohort data shows, and the reverse-causation problem behind it
- Alloy vs Midi Health — cash-pay prescribing against insurance-billed clinical visits
- Alloy review — the $49 consult, every published medication price, and what it never measures
- Alloy cost — year-one and year-two totals by delivery route
- Midi Health review — PPO coverage, labs, clinician credentials, and where coverage stops
- Midi Health cost — self-pay visit pricing against the insured path
Related
- ApoB — the cardiovascular marker that shifts fastest across the transition
- Fasting insulin — insulin resistance appears years before glucose moves
- Lp(a) — the once-in-a-lifetime inherited risk test
- Doctor-led options — physician-supervised platforms compared on one rubric
- Supplements — including the iron and vitamin D questions this panel raises
Frequently Asked Questions
What are the three stages of menopause?
Perimenopause is the transition, usually beginning between 40 and 51 and lasting 4 to 10 years, when cycles change and hormones swing. Menopause is a single retrospective point: 12 consecutive months with no period, at a US median age of 51. Postmenopause is everything after that, when estradiol stays low and bone loss and cardiovascular risk accelerate. Most symptoms people call "menopause" actually belong to perimenopause.
Can a blood test confirm perimenopause?
Not reliably from one draw. FSH and estradiol fluctuate dramatically during the transition — FSH can read menopausal one month and premenopausal the next, and estradiol can spike above normal premenopausal peaks. Perimenopause is a clinical diagnosis based on cycle change and symptoms, in a woman of the right age. Labs are still worth running, but for the reasons below: ruling out thyroid disease and iron deficiency, and establishing metabolic and cardiovascular baselines.
What should be on a perimenopause panel?
FSH, estradiol, progesterone drawn day 19–21 if you are still cycling, total and free testosterone, DHEA-S, a full thyroid panel with TPO antibodies, ferritin and CBC, fasting insulin and HbA1c, and ApoB plus a one-time Lp(a). Vitamin D and B12 are worth adding. The hormone values will move; the thyroid, iron, metabolic and cardiovascular results are the ones that most often change what you do.
What is the HRT timing hypothesis?
Evidence suggests hormone therapy started within about 10 years of the final period, or before age 60, carries a different risk-benefit balance than therapy started later. Started early, it is associated with reduced fracture risk and neutral-to-favorable cardiovascular outcomes. Started 10 to 20 years after menopause, into arteries that already carry established plaque, the cardiovascular picture is less favorable. This window is the single most useful concept in the whole HRT conversation.
Why did doctors stop prescribing HRT?
The 2002 Women's Health Initiative results were reported in a way that produced widespread discontinuation. The trial's average participant was 63 — more than a decade past menopause — and used conjugated equine estrogens with a synthetic progestin. Later re-analysis by age group found substantially different results for women who started in their 50s. Prescribing rates fell by roughly 80% and have never fully recovered, which is why many women today are told to wait it out.
Is bioidentical hormone therapy safer than conventional HRT?
FDA-approved bioidentical products — transdermal estradiol and micronized progesterone — are well studied, and transdermal delivery avoids the first-pass liver effect linked to clotting risk with oral estrogen. Compounded bioidentical preparations are a different thing: they are not FDA-approved, batch potency varies, and salivary hormone monitoring used to guide them is not validated. "Bioidentical" describes the molecule, not the quality control.
What does hormone therapy typically cost?
Generic transdermal estradiol patches run roughly $15–$50 a month and micronized progesterone $20–$60, often with insurance coverage. Compounded creams and pellets are cash-pay: creams around $50–$150 a month, pellets $400–$800 per insertion three to four times a year. Physician-led programs that bundle consults, full panels and monitoring generally run $150–$400 a month before medication.